NASDAQ:SUPN - Supernus Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$36.53 -4.01 (-9.89 %)
(As of 12/10/2018 08:50 AM ET)
Previous Close$40.54
Today's Range$36.00 - $40.96
52-Week Range$34.90 - $61.25
Volume1.79 million shs
Average Volume565,537 shs
Market Capitalization$1.91 billion
P/E Ratio28.99
Dividend YieldN/A
Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy. The company's product candidates comprise SPN-810, a molindone hydrochloride that is in Phase III clinical trial for the treatment of impulsive aggression in patients with attention deficit hyperactivity disorder (ADHD); and SPN-812, a viloxazine hydrochloride, which is in Phase III clinical trial that is used for the treatment of ADHD. It also develops SPN-809, a viloxazine hydrochloride, which is in Phase II ready clinical trial for the treatment of depression. The company markets its products through wholesalers and pharmaceutical distributors. Supernus Pharmaceuticals, Inc. was founded in 2005 and is based in Rockville, Maryland.

Receive SUPN News and Ratings via Email

Sign-up to receive the latest news and ratings for SUPN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Current SymbolNASDAQ:SUPN
Previous Symbol


Debt-to-Equity Ratio0.77
Current Ratio2.82
Quick Ratio2.65


Trailing P/E Ratio28.99
Forward P/E Ratio19.53
P/E Growth1.15

Sales & Book Value

Annual Sales$302.24 million
Price / Sales6.32
Cash Flow$1.4548 per share
Price / Cash Flow25.11
Book Value$5.22 per share
Price / Book7.00


EPS (Most Recent Fiscal Year)$1.26
Net Income$57.28 million
Net Margins25.89%
Return on Equity30.30%
Return on Assets14.34%


Outstanding Shares52,260,000
Market Cap$1.91 billion

Supernus Pharmaceuticals (NASDAQ:SUPN) Frequently Asked Questions

What is Supernus Pharmaceuticals' stock symbol?

Supernus Pharmaceuticals trades on the NASDAQ under the ticker symbol "SUPN."

How were Supernus Pharmaceuticals' earnings last quarter?

Supernus Pharmaceuticals Inc (NASDAQ:SUPN) announced its quarterly earnings data on Tuesday, November, 6th. The specialty pharmaceutical company reported $0.52 EPS for the quarter, beating analysts' consensus estimates of $0.43 by $0.09. The specialty pharmaceutical company earned $102.99 million during the quarter, compared to the consensus estimate of $100.75 million. Supernus Pharmaceuticals had a net margin of 25.89% and a return on equity of 30.30%. The company's quarterly revenue was up 28.1% on a year-over-year basis. During the same quarter last year, the firm posted $0.29 EPS. View Supernus Pharmaceuticals' Earnings History.

When is Supernus Pharmaceuticals' next earnings date?

Supernus Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, February 26th 2019. View Earnings Estimates for Supernus Pharmaceuticals.

What price target have analysts set for SUPN?

8 equities research analysts have issued 1 year price targets for Supernus Pharmaceuticals' shares. Their predictions range from $44.00 to $66.00. On average, they expect Supernus Pharmaceuticals' share price to reach $58.25 in the next twelve months. This suggests a possible upside of 59.5% from the stock's current price. View Analyst Price Targets for Supernus Pharmaceuticals.

What is the consensus analysts' recommendation for Supernus Pharmaceuticals?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Supernus Pharmaceuticals in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Supernus Pharmaceuticals.

What are Wall Street analysts saying about Supernus Pharmaceuticals stock?

Here are some recent quotes from research analysts about Supernus Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland. " (11/8/2018)
  • 2. Cantor Fitzgerald analysts commented, "We anticipate the core Trokendi XR and Oxtellar XR businesses will continue to perform well, particularly the former, with the ongoing roll-out for the migraine prevention indication. Over the next 12-24 months, with provision of positive clinical trial data, we believe investors will better appreciate the value of pipeline assets SPN-810 and SPN-812 and the bipolar indication opportunity for Oxtellar XR." (10/4/2018)
  • 3. Mizuho analysts commented, "We initiate coverage with a Buy rating and $61 PT. We believe Supernus is well-positioned in an attractive CNS market, with a promising pipeline that can drive growth through pending Trokendi XR competition in migraine." (9/17/2018)

Has Supernus Pharmaceuticals been receiving favorable news coverage?

Media headlines about SUPN stock have trended very positive recently, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Supernus Pharmaceuticals earned a news impact score of 3.9 on InfoTrie's scale. They also gave news coverage about the specialty pharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the near future.

Who are some of Supernus Pharmaceuticals' key competitors?

Who are Supernus Pharmaceuticals' key executives?

Supernus Pharmaceuticals' management team includes the folowing people:
  • Mr. Jack A. Khattar, Founder, Pres, CEO, Sec. & Director (Age 57)
  • Mr. Gregory S. Patrick, VP & CFO (Age 67)
  • Dr. Padmanabh P. Bhatt, Chief Scientific Officer and Sr. VP of Intellectual Property (Age 61)
  • Dr. Stefan K. F. Schwabe, Chief Medical Officer and Exec. VP of R&D (Age 66)
  • Dr. Todd Horich M.B.A., Ph.D., VP of Marketing

Who are Supernus Pharmaceuticals' major shareholders?

Supernus Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (15.33%), Vanguard Group Inc. (9.79%), FMR LLC (4.54%), Dimensional Fund Advisors LP (2.56%), Bank of New York Mellon Corp (2.41%) and Glenmede Trust Co. NA (1.90%). Company insiders that own Supernus Pharmaceuticals stock include Gregory S Patrick, Padmanabh P Bhatt, Stefan KF Schwabe and Victor Vaughn. View Institutional Ownership Trends for Supernus Pharmaceuticals.

Which institutional investors are selling Supernus Pharmaceuticals stock?

SUPN stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Prudential Financial Inc., Castleark Management LLC, Acadian Asset Management LLC, JPMorgan Chase & Co., JPMorgan Chase & Co., Bank of New York Mellon Corp and Rice Hall James & Associates LLC. Company insiders that have sold Supernus Pharmaceuticals company stock in the last year include Gregory S Patrick, Padmanabh P Bhatt, Stefan KF Schwabe and Victor Vaughn. View Insider Buying and Selling for Supernus Pharmaceuticals.

Which institutional investors are buying Supernus Pharmaceuticals stock?

SUPN stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Macquarie Group Ltd., Glenmede Trust Co. NA, BlackRock Inc., Vanguard Group Inc., Capital Management Corp VA, Falcon Point Capital LLC and Icon Advisers Inc. Co.. View Insider Buying and Selling for Supernus Pharmaceuticals.

How do I buy shares of Supernus Pharmaceuticals?

Shares of SUPN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Supernus Pharmaceuticals' stock price today?

One share of SUPN stock can currently be purchased for approximately $36.53.

How big of a company is Supernus Pharmaceuticals?

Supernus Pharmaceuticals has a market capitalization of $1.91 billion and generates $302.24 million in revenue each year. The specialty pharmaceutical company earns $57.28 million in net income (profit) each year or $1.26 on an earnings per share basis. Supernus Pharmaceuticals employs 422 workers across the globe.

What is Supernus Pharmaceuticals' official website?

The official website for Supernus Pharmaceuticals is

How can I contact Supernus Pharmaceuticals?

Supernus Pharmaceuticals' mailing address is 1550 E GUDE DR, ROCKVILLE MD, 20850. The specialty pharmaceutical company can be reached via phone at 301-838-2500 or via email at [email protected]

MarketBeat Community Rating for Supernus Pharmaceuticals (NASDAQ SUPN)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  377 (Vote Outperform)
Underperform Votes:  208 (Vote Underperform)
Total Votes:  585
MarketBeat's community ratings are surveys of what our community members think about Supernus Pharmaceuticals and other stocks. Vote "Outperform" if you believe SUPN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SUPN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/10/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel